Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wade Schmidt

Interventional Cardiology St Cloud, MN Medical Doctor

NPI 1629031190 CMS profile 637242

1200 Sixth Ave N, Centracare Clinic, St Cloud, MN 56303

Open in the dashboard

General payments

$8,577

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wade Schmidt of St Cloud, MN is reported in the CMS Open Payments database as having received $8,577 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,112 59
2024 General $1,238 29
2023 General $1,097 28
2022 General $2,857 27
2021 General $271 12
2020 General $344 15
2019 General $658 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wade Schmidt
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Wade Schmidt were reported at $2,112. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Wade Schmidt Interventional Cardiology median Middle half National median
2019 $658 $1,097 $329–$3,048 $163
2020 $344 $473 $161–$1,480 $114
2021 $271 $677 $233–$1,827 $132
2022 $2,857 $978 $333–$2,724 $149
2023 $1,097 $1,136 $382–$2,986 $160
2024 $1,238 $1,181 $395–$3,326 $164
2025 $2,112 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,222 33 payments
  2. Medtronic, Inc. $1,704 60 payments
  3. Edwards Lifesciences Corporation $619 15 payments
  4. Abiomed $595 21 payments
  5. Inari Medical, Inc. $575 11 payments
  6. AngioDynamics, Inc. $528 8 payments
  7. Abbott Laboratories $317 9 payments
  8. Medtronic Vascular, Inc. $317 18 payments
  9. Cardiovascular Systems Inc. $217 9 payments
  10. Inquis Medical, Inc. $170 3 payments
  11. Other $313 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,282 197 payments
  2. Consulting Fee $2,250 1 payment
  3. Gift $45 1 payment
Products named General payments · program years 2019–2025
  1. General - Vascular Access $2,250 1 payment
  2. Micra $620 18 payments
  3. Impella $506 17 payments
  4. ALPHAVAC $427 7 payments
  5. WATCHMAN FLX $400 11 payments
  6. CT THROMBECTOMY SYSTEM KIT $318 5 payments
  7. FLOWTRIEVER CATHETER, S $318 5 payments
  8. COREVALVE EVOLUT R $306 12 payments
  9. SAPIEN 3 Ultra RESILIA $284 6 payments
  10. AZURE XT DR MRI SURESCAN $270 9 payments
  11. Other $2,878 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

542

Median for Cardiology: 2,533

Drug cost

$24,242

Median for Cardiology: $485,213

Branded share of claims

20.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $18,155
Clopidogrel Clopidogrel Bisulfate Brand 67 $1,094
Cilostazol Generic 17 $759
Atorvastatin Calcium Generic 61 $618
Metoprolol Succinate Generic 45 $531
Losartan Potassium Generic 30 $447
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 19 $358
Carvedilol Generic 40 $356
Rosuvastatin Calcium Generic 19 $312
Metoprolol Tartrate Generic 38 $245

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$120,995

Medicare's payments for the services billed

Medicare patients

719

Average age 76

Services billed

1,410

338 women, 381 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Atrial fibrillation 47%
Heart failure 46%
Arthritis 46%
Diabetes 36%
Chronic kidney disease 36%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record